Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Topical tamoxifen in the therapy of cutaneous leishmaniasis

Full text
Author(s):
Trinconi, Cristiana T. [1] ; Reimao, Juliana Q. [1, 2] ; Bonano, I, Vivian ; Espada, Caroline R. [3] ; Miguel, Danilo C. [4, 3] ; Yokoyama-Yasunaka, Jenicer K. U. [3] ; Uliana, Silvia R. B. [3]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Av Prof Lineu Prestes 1374, BR-05508000 Sao Paulo - Brazil
[2] Fac Med Jundiai, Dept Morfol & Patol Basica, Jundiai, SP - Brazil
[3] Bonano, Vivian, I, Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Av Prof Lineu Prestes 1374, BR-05508000 Sao Paulo - Brazil
[4] Univ Estadual Campinas, Inst Biol, Dept Biol Anim, Campinas, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Parasitology; v. 145, n. 4, SI, p. 490-496, APR 2018.
Web of Science Citations: 10
Abstract

The aims of the present work were to test the effect of tamoxifen administered topically and the therapeutic efficacy of tamoxifen and pentavalent antimonial combinations in an experimental model of cutaneous leishmaniasis. BALB/c mice infected with a luciferase expressing line of Lrishmania amazonerisis were treated with topical tamoxifen in two different formulations (cthanol or oil-free cream) as monotherapy or in co-administration with pentavalent antimonial. Treatment efficacy was evaluated by lesion size and parasite burden, quantified through luminescence, at the end of treatment and 4 weeks later. Topical tamoxifen, formulated in ethanol or as a cream, was shown to be effective. The interaction between tamoxifen and pentavalent antimonial was additive in vitro. Treatment with combined schemes containing tamoxifen and pentavalent antimonial was effective in reducing lesion size and parasite burden. Co-administration of tamoxifen and pentavalent antimonial was superior to monotherapy with antimonial. (AU)

FAPESP's process: 11/21970-2 - SELECTIVE ESTROGEN RECEPTOR MODULATORS AS DRUG CANDIDATES FOR VISCERAL LEISHMANIASIS: EVALUATION OF DRUG COMBINATIONS AND INVESTIGATION OF LEISHMANICIDAL MECHANISMS OF ACTION
Grantee:Juliana Quero Reimão Dalla Zanna
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 15/09080-2 - Evaluation of candidate drugs for the treatment of Leishmaniasis in Brazil
Grantee:Silvia Reni Bortolin Uliana
Support type: Regular Research Grants
FAPESP's process: 11/20484-7 - Tamoxifen in the treatment of leishmaniasis: evaluation of efficacy in combination therapy schemes and study of the antileishmanial mechanism of action
Grantee:Silvia Reni Bortolin Uliana
Support type: Regular Research Grants
FAPESP's process: 15/05130-5 - Characterization of Leishmania (v.) braziliensis clinical isolates susceptibility to miltefosine in vitro and in vivo
Grantee:Caroline Ricce Espada
Support type: Scholarships in Brazil - Master
FAPESP's process: 11/18858-6 - TAMOXIFEN AS AN ANTI-LEISHMANIAL DRUG: ACTIVITY IN COMBINED THERAPEUTIC SCHEMES AND STUDY OF THE MECHANISM OF ACTION
Grantee:Cristiana de Melo Trinconi Tronco
Support type: Scholarships in Brazil - Doctorate